Abstract
Traditional medicinal systems have used several plants and their derivatives to treat diseases. This review aims to summarize the available evidence derived from clinical trials of Andrographis. A total of forty clinical trials, involving 5,252 patients, were reviewed for this study, of which 2,621 patients received Andrographis extracts. Out of the total 40 trials, 35 were randomised controlled trials which indicates that Andrographis is clinically beneficial in infectious diseases such as respiratory infections, COVID-19, HIV, hand foot and mouth disease and malaria. Andrographis is also used for metabolic disorders like diabetes and pre-diabetes; neurological disorders like multiple sclerosis and migraine; gastrointestinal diseases like ulcerative colitis and fatty liver diseases. The current review broadens the evidence based clinical applications of A. paniculata which updates the researchers in exploring its clinical benefits.